Express News | NRx Pharmaceuticals Outlines Potential Paths To Revenue And Profitability In 2025; New Shareholder Update Highlights Potential 2024 Revenue From HOPE Therapeutics-Branded Clinics, 2025 Revenue From Sales Of NRX-100 (IV Ketamine) Pending FDA Approval,...
Press Release: NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter PR Newswire RADNOR, Pa., July 1, 2024 -- Potential paths to revenue and profitability in 2025 RADNOR, Pa., July 1, 2024 /PR
Express News | NRX Pharmaceuticals Inc: Nda for NRX-100 in Advanced Preparation for Submission in 2024, Potential Revenue in 2025
Express News | NRX Pharmaceuticals (Nasdaq:Nrxp) to Proceed With Two New Drug Applications in 2024; NRX-101 Has Been Returned to the Company for Filing
Express News | NRX Pharmaceuticals Inc - Agreement Provided for the Joint Development, Supply, Marketing, Commercialization and License to Alvogen of NRX-101
Express News | NRX Pharmaceuticals Inc - Continues to Finalize a New Drug Approval Application for Intravenous Ketamine (NRX-100), to Be Submitted This Year
Express News | NRX Pharmaceuticals- Under Deal, Co, Alvogen Will, Discuss, Negotiate and Seek to Agree to a Royalty Amount Due Alvogen by the Company Within 30 Days
Express News | NRX Pharmaceuticals- Got Notice of Termination of Exclusive, Global – Development, Supply, Marketing & License Agreement, by & Between Co, Alvogen
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical stage pharmaceutical company, today announced that...
Express News | NRX Pharmaceuticals (Nasdaq:Nrxp) Appoints Neuroscience, Information Technology and Medical Technology Veteran to Its Board of Directors
NRx Pharmaceuticals Publishes Shareholder Update Letter; Update Highlights Potential Implications Of The Company's Recent Activities At The Annual Meeting Of The American Society Of Clinical Psychopharmacology
The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of car
Express News | NRX Pharmaceuticals Inc: Expect to Complete Stability Portion of Our New Drug Application for Ketamine by September
Express News | NRX Pharmaceuticals: Reached 9-Month Stability Point With Its Ketamine Formulation (NRX-100), Initiated 3 Manufacturing Lots for Future Drug Release
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the ...
NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital
NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital
Express News | Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $43
NRX Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/07/2024 1094.68% Ascendiant Capital $50 → $43 Maintains Buy 05/25/2023 -44.43% HC Wainwright & Co. → $2
NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 Is the First Oral Antidepressant Demonstrated to Reduce Suicidality in...
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical stage pharmaceutical company, today announced...
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersLucy Scientific Discovery (NASDAQ:LSDI) shares moved upwards by 205.8% to $1.56 during Thursday's regular session. The company's market cap stands at $2.7 million. SINTX Techs (NASDAQ:SINT) sha
NRX Pharmaceuticals Eyes $30M Refinancing and Funding Deal